Patents by Inventor Brendan Lee

Brendan Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11450308
    Abstract: A method for converting text to audio to improve a design of electronic mail messages includes converting, by a text-to-speech converter component executing on a first computing device, an electronic mail message into an audio file. The method includes analyzing, by an analysis engine executing on the first computing device, the electronic mail message, the audio file, and a transcript of the audio file to identify at least one attribute. The method includes receiving, by a recommendation engine executing on the first computing device, an identification of the at least one attribute. The method includes generating, by the recommendation engine, at least one recommendation for improving a design of the electronic mail message, based on the identification of the at least one attribute. The method includes providing, by the first computing device, to a second computing device, the audio file and the generated at least one recommendation.
    Type: Grant
    Filed: April 15, 2020
    Date of Patent: September 20, 2022
    Assignee: Litmus Software, Inc.
    Inventors: Brendan Caffrey, David Lee Rostocil, Jr.
  • Publication number: 20220282280
    Abstract: The present invention relates to gene therapy delivery and expression systems comprising at least one helper-dependent adenoviral vector containing a nucleic acid sequence encoding for proteoglycan 4 (PRG4) or a biologically active fragment thereof. The invention further relates to a pharmaceutical composition comprising a therapeutically effective amount of at least one helper-dependent adenoviral vector containing said nucleic acid sequence encoding for proteoglycan 4 (PRG4), or a homolog thereof from any other species, or a biologically active fragment thereof. The invention also relates to the use of the novel gene therapy delivery and expression system according to the invention fo ruse in the prevention and/or treatment of camptodactyly-arthropathy-coxa vara-pericarditis (CACP), or a musculoskeletal disorder such as a joint disorder or joint disease.
    Type: Application
    Filed: April 1, 2022
    Publication date: September 8, 2022
    Inventors: Merry Ruan, Kilian Guse, Brendan Lee
  • Publication number: 20220282310
    Abstract: Provided herein are methods of detecting and sequencing target nucleic acids in complex samples (e.g., blood), as well as related panels and compositions (e.g., systems, cartridges, and kits).
    Type: Application
    Filed: September 10, 2019
    Publication date: September 8, 2022
    Applicants: T2 Biosystems, Inc., T2 Biosystems, Inc.
    Inventors: Jessica Lee SNYDER, Brendan John MANNING, Christopher STEELE, Roger SMITH, Heidi Susanne GIESE, Yin Shan Cathy WONG, Daniel GAMERO, Thomas J. LOWERY, Jr.
  • Publication number: 20220258525
    Abstract: In an aspect, a marker kit is provided, and includes a plurality of tip holders, a storage member, and an extension member. The tip holders each includes a tip holder body having a connecting portion, and a marker tip extending from the body. The storage member includes a base with a plurality of receptacles, each shaped to removably hold one of the tip holders with the connecting portion exposed. The extension member includes an extension member body for grasping. The extension member body has a securing portion and an actuatable member. The securing portion is releasably connectable to the connecting portion of each tip holder for removal from one of the plurality of receptacles. The actuatable member is for disconnecting the securing portion from the connecting portion of the tip holder that is secured to the extension member so as to release the tip holder back into a receptacle.
    Type: Application
    Filed: December 7, 2021
    Publication date: August 18, 2022
    Inventors: Matthew James CALLAHAN, Vlasta Anastasia KOMOROUS-KING, James Adam SKAATES, Brendan BOYLE, Joshua Lee FINKLE, Andrew Richardson STEWART, Chenyu LIU, Justin Chyun CHANG, Rikki MariaLynn DEVLIN
  • Patent number: 11395026
    Abstract: Systems and methods are disclosed that measure web activity bursts after ad broadcasts that may be sent to multiple persons. One system uses a cookie-less/cookie-optional, anonymous/personal-identification-not-required, method for web-based conversion tracking that will work on broadcast media systems such as television, and could also be applied to measuring spikes from email, radio, and other forms of advertising where an episodic ad event is broadcast to multiple parties, and where responses occur in a batch after the broadcast.
    Type: Grant
    Filed: November 11, 2020
    Date of Patent: July 19, 2022
    Assignee: ADAP. TV, Inc.
    Inventors: Brendan Kitts, Dyng Au, Michael Bardaro, Sawin Lee, Alfred Lee
  • Publication number: 20220195025
    Abstract: The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGF?).
    Type: Application
    Filed: December 9, 2021
    Publication date: June 23, 2022
    Applicants: GENZYME CORPORATION, Baylor College of Medicine
    Inventors: Brendan Lee, Kuber T. Sampath
  • Publication number: 20220073948
    Abstract: The invention relates to an adenoviral-based biological delivery and expression system for use in the treatment or prevention of osteoathritis in human or mammalian joints by long-term inducible gene expression of human or mammalian interleukin-1 receptor antagonist (II-1 Ra) in synovial cells, comprising a helper-dependent adenoviral vector containing a nucleic acid sequence encoding for human or mammalian interleukin-1 receptor antagonist (II-1 Ra), left and right inverted terminal repeats (L ITR and R ITR), the adenoviral packaging signal and non-viral, non-coding stuffer nucleic acid sequences, wherein the expression of the human or mammalian interleukin-1 receptor antagonist (II-1 Ra) gene within synovial cells is regulated by an inflammation-inducible promoter.
    Type: Application
    Filed: October 8, 2021
    Publication date: March 10, 2022
    Inventors: Brendan LEE, Kilian GUSE, Zhechao RUAN
  • Patent number: 11230595
    Abstract: The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGF?).
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: January 25, 2022
    Assignees: Genzyme Corporation, Baylor College of Medicine
    Inventors: Brendan Lee, Kuber T. Sampath
  • Publication number: 20220017923
    Abstract: The present invention relates to gene therapy delivery and expression systems comprising at least one helper-dependent adenoviral vector containing a nucleic acid sequence encoding for proteoglycan 4 (PRG4) or a biologically active fragment thereof. The invention further relates to a pharmaceutical composition comprising a therapeutically effective amount of at least one helper-dependent adenoviral vector containing said nucleic acid sequence encoding for proteoglycan 4 (PRG4), or a homolog thereof from any other species, or a biologically active fragment thereof. The invention also relates to the use of the novel gene therapy delivery and expression system according to the invention for use in the prevention and/or treatment of camptodactyly-arthropathy-coxa vara-pericarditis (CACP), or a musculoskeletal disorder such as a joint disorder or joint disease.
    Type: Application
    Filed: June 25, 2021
    Publication date: January 20, 2022
    Applicant: Baylor College of Medicine
    Inventors: Zhechao RUAN, Kilian GUSE, Brendan LEE
  • Patent number: 10765346
    Abstract: The ability to capture an undistorted image of the foot or foot and ankle is essential to the production of effective custom orthotics and shoes. This patent solves the problem of providing an accurate three-dimensional measurement of an undistorted foot/ankle by using a system involving the automated and controlled orbit of a point cloud capture device around the foot/ankle with the foot/ankle in a non-weight bearing position so as to capture a three-dimensional image.
    Type: Grant
    Filed: May 9, 2019
    Date of Patent: September 8, 2020
    Inventor: Brendan Lee Adams McLaughlin
  • Publication number: 20200265531
    Abstract: Systems and methods for digital property authentication and management are disclosed. A document representing a trade secret may be requested to be registered with a trade secret registry. A document obfuscation value corresponding to the document may be generated and may be registered with a blockchain. A record of the registration may be generated for the trade secret registry. The registry may be searchable and/or offer functionality such as valuation, insurance provision, and/or verification, among other benefits and functionalities.
    Type: Application
    Filed: February 20, 2019
    Publication date: August 20, 2020
    Inventors: Lewis C. Lee, Daniel Crouse, David Craig Andrews, Samuel Cameron Fleming, Samuel John Desmond, Lewis Brendan Lee
  • Publication number: 20200265530
    Abstract: Systems and methods for digital property authentication and management are disclosed. A document representing a trade secret may be requested to be registered with a trade secret registry. A document obfuscation value corresponding to the document may be generated and may be registered with a blockchain. A record of the registration may be generated for the trade secret registry. The registry may be searchable and/or offer functionality such as valuation, insurance provision, and/or verification, among other benefits and functionalities.
    Type: Application
    Filed: February 20, 2019
    Publication date: August 20, 2020
    Inventors: Lewis C. Lee, Daniel Crouse, David Craig Andrews, Samuel Cameron Fleming, Lewis Brendan Lee, Samuel John Desmond
  • Publication number: 20200147016
    Abstract: A method of modulating plasma levels of branched chain amino acids and branched chain alpha-keto acids is disclosed, wherein an ammonia scavenger compound or a salt thereof, for example phenylbutyrate or an even numbered congener thereof or a salt thereof, is administered to an individual in need thereof. In various methods, a decrease in plasma levels of branched chain amino acids and branched chain alpha-keto acids is effected to treat individuals suffering from an inborn error in metabolism of amino acids, such as Maple Syrup Urine Disease, for example.
    Type: Application
    Filed: January 10, 2020
    Publication date: May 14, 2020
    Inventor: Brendan Lee
  • Publication number: 20190389943
    Abstract: The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGF?).
    Type: Application
    Filed: July 1, 2019
    Publication date: December 26, 2019
    Applicants: GENZYME CORPORATION, Baylor College of Medicine
    Inventors: Brendan Lee, Kuber T. Sampath
  • Publication number: 20190376080
    Abstract: The invention relates to an adenoviral-based biological delivery and expression system for use in the treatment or prevention of osteoarthritis in human or mammalian joints by long-term inducible gene expression of human or mammalian interleukin-I receptor antagonist (II-1 Ra) in synovial cells, comprising a helper-dependent adenoviral vector containing a nucleic acid sequence encoding for human or mammalian interleukin-I receptor antagonist (II-I Ra), left and right inverted terminal repeats (L ITR and R ITR), the adenoviral packaging signal and non-viral, non-coding stuffer nucleic acid sequences, wherein the expression of the human or mammalian interleukin-I receptor antagonist (II-I Ra) gene within synovial cells is regulated by an inflammation-inducible promoter.
    Type: Application
    Filed: April 30, 2019
    Publication date: December 12, 2019
    Inventors: Brendan LEE, Kilian GUSE, Zhechao RUAN
  • Patent number: 10377819
    Abstract: The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGF?).
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: August 13, 2019
    Assignees: GENZYME CORPORATION, Baylor College of Medicine
    Inventors: Brendan Lee, Kuber T. Sampath
  • Patent number: 10301647
    Abstract: The invention relates to an adenoviral-based biological delivery and expression system for use in the treatment or prevention of osteoathritis in human or mammalian joints by long-term inducible gene expression of human or mammalian interleukin-1 receptor antagonist (Il-1Ra) in synovial cells, comprising a helper-dependent adenoviral vector containing a nucleic acid sequence encoding for human or mammalian interleukin-1 receptor antagonist (Il-1Ra), left and right inverted terminal repeats (L ITR and R ITR), the adenoviral packaging signal and non-viral, non-coding stuffer nucleic acid sequences, wherein the expression of the human or mammalian interleukin-1 receptor antagonist (Il-1Ra) gene within synovial cells is regulated by an inflammation-inducible promoter.
    Type: Grant
    Filed: January 23, 2013
    Date of Patent: May 28, 2019
    Assignee: Baylor College of Medicine
    Inventors: Brendan Lee, Kilian Guse, Zhechao Ruan
  • Publication number: 20190151268
    Abstract: A method of modulating plasma levels of branched chain amino acids and branched chain alpha-keto acids is disclosed, wherein an ammonia scavenger compound or a salt thereof, for example phenylbutyrate or an even numbered congener thereof or a salt thereof, is administered to an individual in need thereof. In various methods, a decrease in plasma levels of branched chain amino acids and branched chain alpha-keto acids is effected to treat individuals suffering from an inborn error in metabolism of amino acids, such as Maple Syrup Urine Disease, for example.
    Type: Application
    Filed: September 18, 2018
    Publication date: May 23, 2019
    Inventor: Brendan Lee
  • Patent number: 10092532
    Abstract: A method of modulating plasma levels of branched chain amino acids and branched chain alpha-keto acids is disclosed, wherein an ammonia scavenger compound or a salt thereof, for example phenylbutyrate or an even numbered congener thereof or a salt thereof, is administered to an individual in need thereof. In various methods, a decrease in plasma levels of branched chain amino acids and branched chain alpha-keto acids is effected to treat individuals suffering from an inborn error in metabolism of amino acids, such as Maple Syrup Urine Disease, for example.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: October 9, 2018
    Assignee: Baylor College of Medicine
    Inventor: Brendan Lee
  • Publication number: 20170312238
    Abstract: A method of modulating plasma levels of branched chain amino acids and branched chain alpha-keto acids is disclosed, wherein an ammonia scavenger compound or a salt thereof, for example phenylbutyrate or an even numbered congener thereof or a salt thereof, is administered to an individual in need thereof. In various methods, a decrease in plasma levels of branched chain amino acids and branched chain alpha-keto acids is effected to treat individuals suffering from an inborn error in metabolism of amino acids, such as Maple Syrup Urine Disease, for example.
    Type: Application
    Filed: July 18, 2017
    Publication date: November 2, 2017
    Inventor: Brendan Lee